Artivion (AORT)
NYSE:AORT
Top Page
Artivion
(NYSE:AORT)
Select Model
Select Model
Rating:59Neutral
Price Target:
$42.00
▲(16.47% Upside)
Action:ReiteratedDate:02/14/26
The score is driven primarily by improving financial performance and a strong, margin-expansion-focused 2026 outlook from the earnings call. This is tempered by mixed cash-flow quality (free cash flow negative in 2025), bearish technical momentum, and limited valuation support from a negative P/E and no dividend yield data.
Positive Factors
Consistent revenue growth and return to profitability
Sustained top-line growth and a structural return to profitability in 2025 indicate the core business and commercial channels are scaling. Persistent revenue expansion plus positive net income improve cash generation potential and support reinvestment, deleveraging, and long-term operational stability.
Negative Factors
Weak free cash flow and cash conversion
Negative free cash flow despite positive net income signals structural cash conversion inefficiency driven by reinvestments or working capital. This constrains the company’s ability to self-fund growth, deleveraging, or acquisitions and increases reliance on external financing over the medium term.
Read all positive and negative factors
Positive Factors
Negative Factors
Consistent revenue growth and return to profitability
Sustained top-line growth and a structural return to profitability in 2025 indicate the core business and commercial channels are scaling. Persistent revenue expansion plus positive net income improve cash generation potential and support reinvestment, deleveraging, and long-term operational stability.
Read all positive factors
Artivion (AORT) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$1.73B
Dividend YieldN/A
Average Volume (3M)461.50K
Price to Earnings (P/E)211.7
Beta (1Y)0.88
Revenue Growth9.81%
EPS Growth-1067.00%
CountryUS
Employees1,600
SectorHealthcare
Sector Strength45
IndustryMedical - Devices
Share Statistics
EPS (TTM)0.05
Shares Outstanding47,883,896
10 Day Avg. Volume376,123
30 Day Avg. Volume461,498
Financial Highlights & Ratios
PEG Ratio-1.25
Price to Book (P/B)4.61
Price to Sales (P/S)4.69
P/FCF Ratio-2.27K
Enterprise Value/Market Cap1.13
Enterprise Value/Revenue4.43
Enterprise Value/Gross Profit6.96
Enterprise Value/Ebitda33.15
Forecast
1Y Price Target
$51.17Price Target Upside41.90% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)0.45
Revenue Forecast (FY)$494.15M
Artivion Business Overview & Revenue Model
Company Description
Artivion Inc. manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company offers BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular,...
How the Company Makes Money
Artivion generates revenue primarily through the sale of its medical devices and surgical products, which are utilized in hospitals and surgical centers worldwide. The company has established key revenue streams through direct sales to healthcare ...
Artivion Earnings Call Summary
Earnings Call Date:Feb 12, 2026
(Q4-2025)
| % Change Since: |
Next Earnings Date:Apr 30, 2026
Earnings Call Sentiment Positive
The call presented a strong favorable financial and clinical story: double-digit revenue growth, outsized EBITDA expansion, margin improvement, deleveraging, positive clinical data, and clear 2026 guidance. Key challenges remain from the 2024 cybersecurity incident, a softer-than-expected tissue business, an Italian payback adjustment, elevated near-term CapEx and R&D spend, and early-stage commercial execution for new products (AMDS, NEXUS). Overall, positives (growth, margins, clinical/regulatory progress, regional strength, leverage improvement) materially outweigh the operational and legacy headwinds.Positive Updates
Full-Year Revenue and EBITDA Growth
Total adjusted constant currency revenue grew 13% for FY2025 to $443.6M, while adjusted EBITDA grew 26% year-over-year with an adjusted EBITDA margin of 20.2% (up 190 basis points).
Negative Updates
Legacy Cybersecurity Impact
2024 cybersecurity incident negatively impacted revenue by ~$4.5M in Q4 2024 (approximately $2.0M stent grafts and $2.5M tissue processing), complicating year-over-year comps and lingering impacts into 2025.
Read all updates
Q4-2025 Updates
Positive
Negative
Full-Year Revenue and EBITDA Growth
Total adjusted constant currency revenue grew 13% for FY2025 to $443.6M, while adjusted EBITDA grew 26% year-over-year with an adjusted EBITDA margin of 20.2% (up 190 basis points).
Read all positive updates
Company Guidance
Artivion guided 2026 constant‑currency revenue growth of 10–14% (reported revenue $486–$504M) with adjusted EBITDA of $105–$110M (roughly 18–22% growth vs. 2025), implying ~150 bps of adjusted EBITDA margin expansion at the midpoint; gross margin is expected to improve ~50 bps (driven by U.S. AMDS and U.S. On‑X mix), SG&A leverage of ~200 bps, R&D to increase ~100 bps to about 8% of sales, CapEx of approximately $50M (vs. $39M in 2025), free cash flow slightly positive, and interest expense roughly in line with the Q4 exit rate. Product assumptions: tissue flat, BioGlue mid‑single‑digit growth, On‑X mid‑teens, and stent grafts low‑20s; Q1 growth is expected toward the high end of the range with lower, similar growth in Q2–Q4. Guidance excludes any impact from a potential EndoSpan acquisition.Artivion Financial Statement Overview
Summary
Income Statement
66
Positive
Balance Sheet
62
Positive
Cash Flow
44
Neutral
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 441.33M | 388.54M | 354.00M | 313.79M | 298.84M |
| Gross Profit | 270.45M | 248.78M | 229.18M | 202.52M | 197.51M |
| EBITDA | 49.20M | 50.97M | 26.79M | 25.68M | 26.04M |
| Net Income | 9.77M | -13.36M | -30.69M | -19.19M | -14.83M |
Balance Sheet | |||||
| Total Assets | 884.80M | 789.10M | 792.40M | 762.80M | 793.05M |
| Cash, Cash Equivalents and Short-Term Investments | 64.91M | 53.46M | 58.94M | 39.35M | 55.01M |
| Total Debt | 292.04M | 362.26M | 358.34M | 356.83M | 362.04M |
| Total Liabilities | 436.56M | 512.90M | 510.62M | 478.47M | 492.32M |
| Stockholders Equity | 448.23M | 276.20M | 281.78M | 284.33M | 300.73M |
Cash Flow | |||||
| Free Cash Flow | -911.00K | 11.05M | 11.39M | -15.87M | -15.68M |
| Operating Cash Flow | 38.13M | 22.24M | 18.82M | -5.15M | -2.58M |
| Investing Cash Flow | -42.04M | -28.19M | -502.00K | -10.71M | 5.66M |
| Financing Cash Flow | 13.03M | 2.20M | 865.00K | -1.64M | -12.22M |
Artivion Technical Analysis
Negative
36.06
Price Trends
37.70
Negative
41.45
Negative
40.11
Negative
Market Momentum
-0.94
Positive
44.63
Neutral
33.28
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AORT, the sentiment is Negative. The current price of 36.06 is above the 20-day moving average (MA) of 35.83, below the 50-day MA of 37.70, and below the 200-day MA of 40.11, indicating a bearish trend. The MACD of -0.94 indicates Positive momentum. The RSI at 44.63 is Neutral, neither overbought nor oversold. The STOCH value of 33.28 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AORT.
Artivion Risk Analysis
Artivion disclosed 33 risk factors in its most recent earnings report. Artivion reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Artivion Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
68 Neutral | $3.54B | -13.83 | -21.49% | ― | 8.97% | -1024.86% | |
59 Neutral | $1.73B | 211.68 | 2.44% | ― | 9.81% | -1067.00% | |
56 Neutral | $1.76B | -95.98 | -13.44% | ― | 18.72% | 85.77% | |
56 Neutral | $615.22M | -45.38 | -12.91% | ― | 23.27% | 43.90% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | $489.76M | -6.56 | -20.38% | ― | 4.31% | 3.26% | |
47 Neutral | $749.76M | -1.85 | -39.90% | ― | 4.99% | -7151.40% |
* Healthcare Sector Average
AORT
Artivion
36.06
12.11
50.56%
IART
Integra Lifesciences
9.62
-9.57
-49.87%
OFIX
Orthofix Medical
12.20
-2.52
-17.12%
AXGN
AxoGen
34.00
17.24
102.86%
LIVN
LivaNova
64.66
28.94
81.02%
SIBN
SI-Bone
13.93
<0.01
0.07%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.